trigram

This is a table of type trigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.

trigram	frequency
as well as	110
of the trial	98
of clinical trials	85
the use of	81
in clinical trials	77
the number of	74
in patients with	69
the treatment of	67
trial and error	65
the impact of	62
in order to	60
need to be	59
of the pandemic	52
of the study	51
during the covid	50
versus standard care	50
to participate in	48
based on the	48
in the trial	47
evidence of a	47
severe acute respiratory	47
there is a	46
according to the	46
serious adverse events	45
efficacy and safety	42
due to the	42
as a result	42
patients with covid	41
in terms of	40
clinical trials in	40
randomized controlled trial	40
and safety of	39
acute respiratory syndrome	39
respiratory distress syndrome	38
the united states	37
of patients with	36
the risk of	36
randomised controlled trials	36
the majority of	35
for the treatment	35
the effect of	34
the time of	33
respiratory syndrome coronavirus	33
data will be	33
acute respiratory distress	33
treatment of covid	33
in the treatment	32
world health organization	32
randomized clinical trial	32
one of the	32
a number of	32
in addition to	31
the need for	31
trial sequential analysis	30
a systematic review	30
randomised controlled trial	30
such as the	30
the role of	30
in accordance with	30
showed evidence of	30
in the united	29
of the trials	29
participants will be	28
in the first	28
the first trial	28
clinical trials during	28
the results of	28
during the pandemic	28
there is no	28
chronic obstructive pulmonary	27
the possibility of	27
obstructive pulmonary disease	27
a total of	27
of the covid	27
there was no	26
the conduct of	26
the context of	26
trial of phase	26
be used to	26
the end of	26
impact of the	26
may not be	26
the effects of	26
randomized clinical trials	26
at the time	25
in developing countries	25
of clinical research	25
the control group	25
understanding of the	25
the absence of	25
risk of bias	25
critically ill patients	24
acute respiratory failure	24
accordance with the	24
randomized controlled trials	24
no evidence of	24
the basis of	24
included in the	24
food and drug	24
for clinical trials	24
the management of	24
analysis of the	24
clinical trials and	24
the clinical trial	23
the primary outcome	23
a result of	23
trial will be	23
related to the	23
quality of life	23
standard of care	23
first trial of	23
and drug administration	23
it may be	23
the duration of	22
clinical trials for	22
that can be	22
of the intervention	22
to assess the	22
beneficial effect of	22
proportion of patients	22
clinical trials of	22
of clinical trial	22
a lack of	22
of a beneficial	22
in the study	22
a clinical trial	21
phase iii trials	21
the quality of	21
very low certainty	21
high risk of	21
the development of	21
nonserious adverse events	21
twice daily for	21
with acute respiratory	21
a beneficial effect	21
standard care on	21
of a difference	20
will be conducted	20
the trial will	20
days after randomization	20
in the context	20
on the basis	20
may need to	20
the live home	19
with severe covid	19
results of a	19
end of the	19
conduct of clinical	19
because of the	19
patients will be	19
controlled trial of	19
likely to be	19
to evaluate the	19
the importance of	19
part of the	19
remdesivir versus placebo	19
in this study	19
for patients with	19
a randomized clinical	19
be able to	19
of the task	19
for the trial	18
during a pandemic	18
will be used	18
three age groups	18
of hydroxychloroquine in	18
some of the	18
to ensure that	18
will be performed	18
of missing data	18
standard care alone	18
will need to	18
the implementation of	18
the trial is	18
of the data	18
a difference between	18
living systematic review	18
the efficacy of	17
analysis showed no	17
the copyright holder	17
phase ii trials	17
to standard care	17
in the absence	17
to the pandemic	17
standard care versus	17
the course of	17
should be considered	17
of safety data	17
the process of	17
may also be	17
to be considered	17
well as the	17
will not be	17
care versus standard	17
added to standard	17
the world health	17
to display the	17
most of the	17
this article is	17
of coronavirus disease	17
acute lung injury	17
patients with severe	17
approved by the	16
clinical trials are	16
on serious adverse	16
the safety of	16
it is not	16
relative risk reduction	16
we found that	16
systematic review of	16
a trial of	16
below the ball	16
the need to	16
needs to be	16
in clinical research	16
the trial and	16
the proportion of	16
the potential for	16
showed no evidence	16
we did not	16
in critically ill	16
systematic review and	16
at least one	16
children with acute	16
with regard to	16
as part of	16
this is a	16
total number of	16
on clinical trials	16
institutional review boards	16
the research team	16
depending on the	16
of this article	16
safety and efficacy	16
good clinical practice	16
trials in phase	16
of this study	16
the patient is	15
in light of	15
in response to	15
there may be	15
granted medrxiv a	15
the total number	15
hospitalized patients with	15
a randomized controlled	15
will be collected	15
holder for this	15
license to display	15
willingness to participate	15
in this trial	15
the design of	15
has granted medrxiv	15
impact on the	15
a license to	15
it is important	15
the preprint in	15
trials in the	15
in relation to	15
copyright holder for	15
due to covid	15
display the preprint	15
is important to	15
preprint in perpetuity	15
by the pandemic	15
results from the	15
a review of	15
who has granted	15
for this preprint	15
medrxiv a license	15
access to the	14
can be found	14
of chronic obstructive	14
made available under	14
from the trial	14
the trial results	14
in the same	14
results of the	14
is likely to	14
the most efficient	14
use of the	14
members of the	14
intermittent preventive treatment	14
versus placebo on	14
the analysis of	14
east respiratory syndrome	14
available under a	14
is defined as	14
around the world	14
was associated with	14
clinical trials that	14
the start of	14
required information size	14
after randomization in	14
the lack of	14
it is made	14
a range of	14
in the case	14
is made available	14
of the vaccine	14
with or without	14
be carried out	14
none of the	14
international license it	14
ongoing clinical trials	14
middle east respiratory	14
the authors declare	14
associated with a	14
license it is	14
can be used	14
treatment of patients	14
no significant difference	14
of the clinical	14
will also be	14
the miracle trial	13
randomization in the	13
number of trials	13
the presence of	13
the treatment effect	13
the university of	13
analysis showed that	13
of a randomized	13
a way that	13
the effectiveness of	13
not possible to	13
it would be	13
participants in the	13
the ability to	13
based on a	13
european medicines agency	13
will be reported	13
the most common	13
at the same	13
prior to the	13
the fact that	13
traditional chinese medicine	13
of trials in	13
should not be	13
of trial and	13
of these trials	13
the case of	13
review and meta	13
the scientific community	13
the novel coronavirus	13
a variety of	13
of adverse events	13
half of the	13
malaria in pregnancy	13
whether or not	13
for treatment of	13
with respect to	13
masks and respirators	13
in the us	13
implementation of the	13
clinical trial of	13
treatments for covid	13
of the disease	12
version posted june	12
analysis of safety	12
morbidity and mortality	12
of the primary	12
at high risk	12
this version posted	12
in line with	12
claims in published	12
for the first	12
the prevention of	12
it is also	12
a phase iii	12
to the trial	12
to clinical trials	12
review of the	12
as compared with	12
and serious adverse	12
in published maps	12
number of days	12
this preprint this	12
trials during the	12
each of the	12
the author funder	12
at the end	12
one or more	12
and treatment of	12
published maps and	12
the validity of	12
to jurisdictional claims	12
to do so	12
large number of	12
in the event	12
was no significant	12
on the trial	12
regard to jurisdictional	12
in a way	12
ensure that the	12
impact of covid	12
adverse events in	12
in which the	12
maps and institutional	12
there is an	12
in phase i	12
it has been	12
and institutional affiliations	12
in the control	12
remains neutral with	12
a combination of	12
is based on	12
is the author	12
related to covid	12
springer nature remains	12
jurisdictional claims in	12
neutral with regard	12
type i error	12
nature remains neutral	12
preprint this version	12
was used to	12
use of it	12
focus on the	12
the cumulative z	12
that it is	12
the pangolin could	12
will be provided	11
intensive care unit	11
to make a	11
it was not	11
many of the	11
that they have	11
risk of infection	11
of the drug	11
source data verification	11
it will be	11
daily for days	11
and exclusion criteria	11
patients with acute	11
the full protocol	11
to minimize the	11
start of the	11
used the same	11
d proportion of	11
and measures to	11
trials of surfactant	11
for the primary	11
data and safety	11
participate in the	11
a is the	11
participate in clinical	11
note springer nature	11
more likely to	11
characteristics of the	11
trials in which	11
data from the	11
in the design	11
of the evidence	11
during the trial	11
for healthcare workers	11
suggests that the	11
as soon as	11
their first trial	11
no competing interests	11
in treatment of	11
people with dementia	11
showed that we	11
number of participants	11
respiratory syncytial virus	11
of a trial	11
be used for	11
has been shown	11
public health emergency	11
the outcome of	11
of mechanical ventilation	11
statement of intent	11
under a is	11
protocol for a	11
will be recorded	11
the statistical analysis	11
individual patient data	11
hospitalized with severe	11
that there is	11
in a trial	11
the same time	11
may lead to	11
the experimental group	11
there are no	11
in children with	11
patients admitted to	10
clinical research in	10
could also be	10
plot and measures	10
the efficacy and	10
to be more	10
this paper at	10
adults hospitalized with	10
measures to quantify	10
if there is	10
authors declare that	10
during this pandemic	10
to confirm or	10
during the study	10
the timing of	10
international conference on	10
to quantify heterogeneity	10
clinical trials registry	10
they have no	10
use of a	10
be considered as	10
the forest plot	10
which may be	10
of masks and	10
used in the	10
the purpose of	10
declare that they	10
validity of the	10
international clinical trials	10
analysis of trials	10
inclusion and exclusion	10
and efficacy of	10
the informed consent	10
in the face	10
for those who	10
a relative risk	10
the patient will	10
response to the	10
to ensure the	10
by the covid	10
in pharmaceutical companies	10
enough information to	10
information about the	10
of the forest	10
to the study	10
in the future	10
of novel coronavirus	10
during the current	10
clinical characteristics of	10
the developing world	10
participated in the	10
and reporting of	10
the task and	10
data monitoring committee	10
there was a	10
analyses will be	10
inspection of the	10
and in the	10
in hospitalized patients	10
clinical trials on	10
and will be	10
systematic reviews and	10
in the field	10
the face of	10
be found in	10
hydroxychloroquine versus standard	10
will be compared	10
of patients and	10
the pandemic and	10
in a clinical	10
the case for	10
the trial was	10
time to clinical	10
the spread of	10
institutes of health	10
straws below the	10
data collection and	10
for the prevention	10
of surfactant in	10
forest plot and	10
head and neck	10
the introduction of	10
in the analysis	10
to address the	10
days will be	10
paper at https	10
the study will	10
this study is	10
hydroxychloroquine in patients	10
if it is	10
patients with dementia	10
visual inspection of	10
data should be	10
consent to participate	10
many of these	9
on how to	9
we argue that	9
or in the	9
trials should be	9
evaluation of the	9
of trials of	9
and there is	9
of a vaccine	9
effects of the	9
of the live	9
participation in the	9
more than one	9
patients in the	9
in the covid	9
are likely to	9
we focus on	9
significant difference in	9
of medical products	9
sample size of	9
number of patients	9
the second trial	9
were included in	9
in collaboration with	9
to the patient	9
that do not	9
data on the	9
mg kg twice	9
statistical analysis of	9
of picu stay	9
duration of picu	9
the clinical trials	9
time of writing	9
and their caregivers	9
of the research	9
study protocol for	9
included in this	9
moderate to severe	9
changes in the	9
in this case	9
difference in the	9
sequential analysis showed	9
with the task	9
the younger children	9
the three age	9
is that the	9
schmitz et al	9
conducting clinical trials	9
kg twice daily	9
is the first	9
with the same	9
will be presented	9
the aim of	9
cancer clinical trials	9
acute exacerbation of	9
confirm or reject	9
safety monitoring board	9
the it artefact	9
risk reduction of	9
with a relative	9
collaboration with the	9
in a pandemic	9
involved in the	9
study of the	9
course of the	9
the current pandemic	9
this is the	9
the pandemic on	9
of undue influence	9
the sample size	9
the intervention period	9
analysis showed evidence	9
influenced by the	9
a randomized trial	9
us food and	9
on the management	9
national institutes of	9
with the aim	9
trials registry platform	9
central statistical monitoring	9
case report form	9
that may be	9
use of masks	9
the protection of	9
will be assessed	9
any of the	9
patients with the	9
did not cross	9
patients treated with	9
the steering committee	9
treatment for covid	9
policy trial emulation	9
and safety monitoring	9
of health and	9
to clinical improvement	9
in the clinical	9
is not possible	9
to use the	9
this statement of	9
of the treatment	9
the choice of	9
serious adverse event	9
due to a	9
statistical analysis plan	9
and trial sequential	9
the ball and	9
by the number	9
in adults hospitalized	9
who cannot take	9
could not be	9
of participants in	9
distrust in pharmaceutical	9
trials of medical	9
associated with the	9
in adults with	9
not cross the	9
nature of the	9
in the second	9
to have a	9
the field of	9
trials can be	9
are able to	9
of informed consent	9
health care workers	9
a hypothetical strategy	9
the severe acute	9
the success of	9
the characteristics of	9
during the first	9
role in the	9
to the intervention	9
may be considered	9
is expected to	9
will have to	9
to meet the	9
of bubonic plague	8
days of the	8
the trial design	8
be required to	8
written informed consent	8
of lopinavir ritonavir	8
the pandemic in	8
proportion of trials	8
to receive the	8
the ards network	8
to support the	8
serious adverse reactions	8
lopinavir ritonavir and	8
of randomised controlled	8
the location of	8
guidance on the	8
of public health	8
light of the	8
was not possible	8
as at high	8
it should be	8
assessed as at	8
for each trial	8
the pharmaceutical industry	8
results from a	8
so as to	8
duration of ventilation	8
experience with the	8
repurposed for covid	8
will be the	8
of the safety	8
a minimum of	8
medical products during	8
possible to perform	8
the event of	8
patients with moderate	8
the trials were	8
be given to	8
will be made	8
effect of hydroxychloroquine	8
a set of	8
trial randomizing participants	8
with the tablet	8
treatment of malaria	8
the us food	8
action sequence in	8
the study is	8
trial of lopinavir	8
clinical research and	8
there has been	8
the case report	8
analysis will be	8
of severe acute	8
the data protection	8
in critical care	8
the identification of	8
the aim to	8
care on serious	8
throughout the trial	8
the included trials	8
some of these	8
trials may be	8
will be randomized	8
by the research	8
as source control	8
for mechanical ventilation	8
outcomes will be	8
an opportunity to	8
the european medicines	8
where the user	8
of vaccine protection	8
member of the	8
will be assigned	8
the value of	8
and public health	8
increased risk of	8
information accompanies this	8
responsible for the	8
the second stage	8
and missing data	8
data protection regulation	8
a serious adverse	8
in clinical trial	8
on the ipad	8
the opportunity to	8
when they are	8
trial steering committee	8
has not been	8
affected by the	8
and may be	8
is not a	8
to identify the	8
the primary analysis	8
to the research	8
on nonserious adverse	8
at any time	8
be associated with	8
supplementary information accompanies	8
has been used	8
of vaccine candidates	8
most of these	8
accompanies this paper	8
are based on	8
we used the	8
surfactant in children	8
approval of the	8
sponsors and investigators	8
in spite of	8
institutional review board	8
weighted mean difference	8
across the three	8
high level of	8
products during covid	8
management of clinical	8
so that the	8
trial is to	8
addition to the	8
d and d	8
those who cannot	8
not included in	8
the principle of	8
clinical trial sponsors	8
clinical trial designs	8
this may be	8
out of the	8
in the experimental	8
within days will	8
on adverse events	8
prevention and treatment	8
proportion of participants	8
need to take	8
the name of	8
in additional file	8
should be given	8
in this paper	8
all three age	8
approval from the	8
and interpretation of	8
society and conservation	8
intravenous vitamin c	8
the primary endpoint	8
trials have been	8
a randomised controlled	8
between the two	8
the availability of	8
from the patient	8
related missing data	8
novel coronavirus pneumonia	8
efficacy of a	8
of patients who	8
given that the	8
development of the	8
the data will	8
from the study	8
in the community	8
reviews and meta	8
personal protective equipment	8
in a timely	8
the trial sequential	8
to use a	8
of the most	8
in health care	8
n a l	7
in both the	7
make a choice	7
the benefit of	7
were assessed as	7
surfactant was associated	7
there are many	7
university of oxford	7
renal replacement therapy	7
and observational studies	7
uncorrected axillary temperature	7
of hydroxychloroquine on	7
adjusted required information	7
are included in	7
caused by the	7
in contrast to	7
that cannot be	7
of dead ants	7
o u r	7
of randomized controlled	7
the belmont report	7
trial should be	7
a high level	7
the two groups	7
as long as	7
in phase ii	7
ill patients with	7
that the pangolin	7
for the pwd	7
cause mortality and	7
is that of	7
clinical trials to	7
the it device	7
adverse events with	7
most efficient method	7
and days after	7
to health care	7
wolters kluwer health	7
of trial results	7
withdraw from the	7
this can be	7
of the efficacy	7
trials that were	7
as defined by	7
and institutional review	7
recruitment and retention	7
informed consent to	7
in recent years	7
of the present	7
of data collection	7
preventive treatment of	7
will take place	7
die within days	7
results will be	7
ebola virus disease	7
adverse events and	7
the placebo group	7
is a major	7
in the time	7
provided with standard	7
in each group	7
trial sequential monitoring	7
days number of	7
versus medical management	7
p r o	7
may be needed	7
primary outcome measure	7
of the total	7
that they are	7
to provide a	7
to be the	7
which is a	7
in the live	7
clinical trial research	7
followed by ciprofloxacin	7
guidance for industry	7
to describe the	7
that are not	7
on the registry	7
care on all	7
summary of the	7
on conduct of	7
trial has been	7
is associated with	7
be treated with	7
the main trial	7
context of the	7
in randomised controlled	7
unauthorized reproduction of	7
will be sent	7
and type ii	7
to reduce the	7
with a deviated	7
duration of mechanical	7
the safety and	7
on behalf of	7
efficacy of hydroxychloroquine	7
p r e	7
of the statistical	7
missing data in	7
the certainty of	7
trials in developing	7
trials that are	7
we believe that	7
and the impact	7
the clinical study	7
regardless of whether	7
this study was	7
can be ethically	7
in the eu	7
sample size and	7
effect of dexamethasone	7
surgical clinical trials	7
in a similar	7
for systematic reviews	7
of human subjects	7
to investigate the	7
was a significant	7
the status of	7
assigned the value	7
at the university	7
to determine the	7
of the sites	7
same action sequence	7
l p r	7
phase i trials	7
and error behaviour	7
trial design and	7
of registered trials	7
the study and	7
to increase the	7
supported by the	7
carried out in	7
the first days	7
for clinical research	7
using the tablet	7
assessment of the	7
tumor necrosis factor	7
urgent need for	7
a l p	7
interaction with the	7
of in the	7
and that the	7
phase iii trial	7
that of the	7
certainty of the	7
before and after	7
of the nasal	7
the patient and	7
a measure of	7
to take part	7
treatment of severe	7
such as those	7
would need to	7
declaration of helsinki	7
the beginning of	7
in more than	7
explanation and elaboration	7
it is the	7
the time to	7
potential treatments for	7
patients and the	7
and the data	7
is especially important	7
j o u	7
patients who die	7
of negative disconfirmation	7
author impact score	7
be conducted in	7
r n a	7
with azithromycin and	7
were able to	7
trials are needed	7
on the use	7
a deviated septum	7
the amount of	7
differences in the	7
in the medical	7
based on their	7
version of the	7
to complete the	7
to define the	7
result of the	7
may have been	7
research ethics committee	7
primary and secondary	7
research and development	7
used an efficient	7
the rest of	7
will be available	7
the current covid	7
for participation in	7
can lead to	7
trial and days	7
in the presence	7
a living mapping	7
of malaria in	7
exacerbation of copd	7
the decision to	7
first trial and	7
be used in	7
days after enrollment	7
reproduction of this	7
duration of the	7
these trials are	7
of remdesivir versus	7
clinical trials have	7
of life in	7
for the study	7
the benefits of	7
they can be	7
in the previous	7
development of a	7
treatment effects in	7
ritonavir in adults	7
guidance on conduct	7
of the new	7
in the s	7
who die within	7
the evidence was	7
clinical trials is	7
the implementation process	7
compared to the	7
the potential to	7
a framework for	7
have no competing	7
study is to	7
missing data and	7
of the patients	7
used as a	7
free days number	7
u r n	7
hospitalised patients with	7
number of covid	7
it is possible	7
based quality management	7
the definition of	7
r o o	7
be assigned the	7
the recovery trial	7
safety data in	7
are needed to	7
in the protocol	7
sequential monitoring boundaries	7
the reviewed trials	7
patients who have	7
a series of	7
o o f	7
in these trials	7
article is prohibited	7
can only be	7
to determine whether	7
clinical trial data	7
research in the	7
to be used	7
the pangolins were	7
clinical trial results	7
pwds and their	7
group will be	7
the required information	6
to the extent	6
the assessment of	6
and error is	6
when there is	6
of the effect	6
at the site	6
when the trial	6
trial emulation framework	6
the kcdc guideline	6
the acute respiratory	6
indicated no heterogeneity	6
red outward sloping	6
x x x	6
shortness of breath	6
trials for covid	6
to allow for	6
led clinical trials	6
in our study	6
characterized by a	6
of the epidemic	6
iv twice daily	6
of treatment effect	6
are required to	6
the clinical research	6
prophylaxis with azithromycin	6
patient safety and	6
as an additional	6
results of an	6
of the main	6
similar to the	6
on the conduct	6
how do we	6
should be taken	6
trials related to	6
conducted in accordance	6
in hospitalised patients	6
lung injury and	6
article is protected	6
line shows conventional	6
risk of death	6
where there is	6
for safety data	6
within the first	6
not have enough	6
proactive prophylaxis with	6
type of trial	6
on or before	6
of this approach	6
use of hydroxychloroquine	6
the safety profile	6
of patients experiencing	6
mechanical ventilation in	6
the most important	6
be the case	6
the performance of	6
used to assess	6
quality clinical trials	6
this will be	6
adverse events not	6
be interpreted with	6
benefit or harm	6
to contribute to	6
with standard supportive	6
patients experiencing a	6
was based on	6
the k th	6
trials on covid	6
exacerbations of chronic	6
made efficient responses	6
can be considered	6
have access to	6
risk ratio reduction	6
small sample size	6
for the duration	6
trial a randomized	6
care and research	6
trial design for	6
the coronavirus pandemic	6
should be interpreted	6
the trial has	6
consent to research	6
in using the	6
disease in china	6
and the need	6
the treating physician	6
in the academic	6
to the protocol	6
daily for those	6
whether the patient	6
action sequences in	6
can also be	6
of the impact	6
analysis and reporting	6
due to pandemic	6
data management and	6
of respiratory failure	6
of the following	6
preferred reporting items	6
there is also	6
that were efficient	6
are eligible for	6
patients with a	6
registered in the	6
the likelihood of	6
reject that hydroxychloroquine	6
daris was calculated	6
be performed on	6
stages of the	6
of participants and	6
to account for	6
is a clear	6
immortal time bias	6
described in the	6
a harmful effect	6
this pandemic has	6
the evolution of	6
participation in clinical	6
whether it is	6
calculated based on	6
trial of the	6
in this review	6
a spectrum of	6
which was not	6
we performed a	6
the primary objective	6
contribute to the	6
of copd exacerbation	6
ritonavir and interferon	6
sloping red lines	6
trials randomizing patients	6
use is not	6
the coordinator will	6
in control group	6
we do not	6
in the primary	6
and of the	6
of the children	6
controlled trials in	6
early phase clinical	6
one single trial	6
to the patients	6
that there was	6
group randomised trials	6
as shown in	6
dose of mg	6
effect of remdesivir	6
between care and	6
the live intervention	6
an array of	6
in dementia care	6
it is of	6
the containers were	6
phase iib trials	6
cannot take oral	6
of remdesivir for	6
immune responses in	6
as one of	6
chimpanzees and gorillas	6
who international clinical	6
within days of	6
we expect the	6
that the tablet	6
the data and	6
the coronavirus disease	6
monitoring boundaries for	6
the completion of	6
the results were	6
the nature of	6
referred to as	6
reporting items for	6
for the use	6
effect of the	6
protected by copyright	6
all of the	6
the incidence of	6
used for the	6
or before d	6
before d proportion	6
during the intervention	6
placebo on serious	6
was calculated based	6
the magnitude of	6
experiencing a serious	6
on day and	6
is a key	6
a dose of	6
it is imperative	6
of a phase	6
will be analyzed	6
clinical trial registry	6
in cancer patients	6
for human use	6
to improve the	6
social network analysis	6
factors associated with	6
is characterized by	6
period of time	6
safety data analysis	6
in a single	6
phase clinical trials	6
for cancer patients	6
in this context	6
face mask use	6
all data will	6
green dotted line	6
trial with a	6
exclude the possibility	6
to find the	6
the trial in	6
of trials that	6
no role in	6
the nairos trial	6
this trial is	6
conference on harmonisation	6
ratio reduction of	6
respiratory failure in	6
will be asked	6
a proportion of	6
the participants will	6
at this time	6
boundaries for benefit	6
in this setting	6
of the population	6
sample size is	6
number of confirmed	6
of trial participants	6
the impact on	6
across the world	6
the standard of	6
dexamethasone versus standard	6
the daris was	6
the who international	6
the type of	6
were not included	6
and the first	6
i error of	6
first days after	6
such as a	6
in doing so	6
pneumonia in wuhan	6
will be evaluated	6
to investigate whether	6
have not been	6
controlled clinical trial	6
intention to treat	6
the eligible trials	6
to review the	6
information is available	6
participants in control	6
ritonavir versus standard	6
has been a	6
is in the	6
guidelines for reporting	6
by the caregiver	6
at all times	6
in clinical studies	6
the green dotted	6
to focus on	6
would like to	6
parallel group randomised	6
a summary of	6
to be able	6
evidence base for	6
guidelines for the	6
of this paper	6
number of straws	6
trial sequential analyses	6
for which the	6
events not considered	6
presented with the	6
extent to which	6
information size was	6
adhere to the	6
clinical trials should	6
of the patient	6
of days within	6
in clinical practice	6
the patients in	6
remdesivir for the	6
mild to moderate	6
take place in	6
bagayogo et al	6
is protected by	6
the difference between	6
dotted line shows	6
for research participation	6
distinction between care	6
a call for	6
and to the	6
if a patient	6
in this article	6
not be able	6
safety of the	6
invasive mechanical ventilation	6
at the national	6
type ii error	6
shows conventional boundaries	6
the planning of	6
analyses should be	6
contributed to the	6
combination of lopinavir	6
being repurposed for	6
general data protection	6
aim of this	6
the evidence base	6
chemoprevention in pregnancy	6
interventions for treatment	6
different types of	6
placebo on all	6
electronic medical records	6
the same action	6
sequential analysis on	6
of a study	6
is an urgent	6
patient data meta	6
all rights reserved	6
clinical trials the	6
difference between the	6
the trial emulation	6
the efficiency of	6
the principal investigator	6
metastatic colorectal cancer	6
clinical trials using	6
can be achieved	6
infection in the	6
between d and	6
the dexamethasone group	6
that could be	6
of relevant data	6
but it is	6
items for systematic	6
of medical sciences	6
trials were assessed	6
in many ways	6
lead to a	6
cross the trial	6
statistical methods for	6
in the public	6
expected to be	6
the trial sponsor	6
for reporting parallel	6
this is not	6
is funded by	6
been shown to	6
on the other	6
a member of	6
the trial protocol	6
trials alongside genv	6
persons with dementia	6
conduct of the	6
of the nose	6
an impact on	6
is shown in	6
of the it	6
clinical trial design	6
to be a	6
day and day	6
to each other	6
ii error of	6
and conservation of	6
is required for	6
in the literature	6
principles for clinical	6
for adverse events	6
standard supportive care	6
in other countries	6
reduction of in	6
of the technology	6
retrospective cohort study	6
do not receive	6
the benefits and	6
should be conducted	6
they will be	6
control group of	6
of the virus	6
an urgent need	6
a reduction in	6
goal is to	6
reporting parallel group	6
event on or	6
when they were	6
with a median	6
by the trial	6
for benefit or	6
with missing data	6
the approval of	6
days within the	6
of phase i	6
protection of human	6
the trial statistician	6
the two containers	6
trials were registered	6
in the standard	6
clinical trial is	6
comply with the	6
adverse event on	6
did not have	6
with dementia and	6
has been reported	6
may be more	6
emerging infectious diseases	6
the publication of	6
be reported as	6
the target infection	6
collection and analysis	6
in the developing	6
a case study	6
in the uk	6
the survey was	6
with a combination	6
be obtained from	6
updated guidelines for	6
the intensive care	6
primary outcome of	6
for the purpose	6
in studies of	6
is required to	6
living mapping of	6
randomisation will be	6
number of authors	6
therapies in the	6
adaptive clinical trials	6
a large number	6
that the trial	6
based on an	6
patients who are	6
the extent to	6
the relationship between	6
and did not	6
common terminology criteria	5
details of the	5
intensive care units	5
analyses and trial	5
focused on the	5
design of the	5
take into account	5
primary completion date	5
and healthcare products	5
effect of age	5
measured by the	5
are used to	5
trials in korea	5
on the same	5
of the global	5
they may be	5
data may be	5
false discovery rate	5
primary outcome is	5
a living systematic	5
risk factors for	5
enrollment when patients	5
in bubo size	5
due to high	5
for the development	5
this is an	5
target trial emulation	5
may be less	5
the corresponding author	5
objective of the	5
cluster randomised trial	5
of trials for	5
be followed up	5
severe plaque psoriasis	5
orally twice daily	5
south and southeast	5
wedge futility line	5
clinical trial participants	5
defined as the	5
be provided with	5
be transferred to	5
medical research council	5
mortality and serious	5
available from the	5
the future of	5
before the peak	5
the length of	5
approved the final	5
of the tablet	5
the change in	5
shown to be	5
and error may	5
divided by the	5
participation in a	5
workshop on trade	5
patients do not	5
have enough information	5
of it devices	5
can be made	5
the study treatment	5
of a new	5
information to confirm	5
is available to	5
of this manuscript	5
the interest in	5
should be documented	5
of confirmed probable	5
may be particularly	5
creative commons licence	5
the assessment time	5
have been the	5
clinical trial reporting	5
lack of relevant	5
as in the	5
be difficult to	5
clinical trials research	5
in the last	5
beaudry and pinsonneault	5
these types of	5
the sunda pangolin	5
in the early	5
in patients treated	5
the academic literature	5
randomised clinical trial	5
the scope of	5
systemic lupus erythematosus	5
and clinical trials	5
hand hygiene alone	5
for malaria prevention	5
a multicomponent intervention	5
ferneley and sobreperez	5
compared with the	5
with severe acute	5
reporting of the	5
for the final	5
be important to	5
has shown that	5
the setting of	5
we note that	5
dementia and their	5
in the population	5
not want to	5
was to remove	5
the usefulness of	5
the same task	5
outcome of the	5
the cost of	5
recruitment bias in	5
randomised clinical trials	5
trials may also	5
is difficult to	5
outcome was assessed	5
involving human subjects	5
of efficacy or	5
for people with	5
to achieve the	5
with a high	5
of a single	5
is necessary to	5
and clinical research	5
of a pandemic	5
an efficient solution	5
the first two	5
for human research	5
products regulatory agency	5
the outcome was	5
the international conference	5
study will be	5
trial completion latency	5
only two straws	5
compassionate use of	5
for the protection	5
standard protocol items	5
there are several	5
as discussed above	5
the responsibility of	5
admitted to hospital	5
a pandemic is	5
have led to	5
of rcts in	5
be used as	5
initial negative disconfirmation	5
trade and conservation	5
be randomized to	5
the integrity of	5
pangolins native to	5
are essential to	5
the administration of	5
trials did not	5
may be a	5
in the intervention	5
be delivered by	5
main limitation of	5
also need to	5
will be measured	5
data safety monitoring	5
over half of	5
revealed that there	5
results on clinicaltrials	5
of thousands of	5
rather than a	5
ii trials may	5
adaptive structuration theory	5
scientific community to	5
institutional affiliations we	5
with their first	5
of days of	5
of age on	5
following negative disconfirmation	5
allocated to the	5
would not be	5
admitted to the	5
during a shift	5
implications of the	5
at d proportion	5
native to south	5
dexamethasone and remdesivir	5
and quality of	5
clinical trials conducted	5
loss to follow	5
united states food	5
risks of systematic	5
the ethics committee	5
clinical study nurse	5
the testing chamber	5
evidence from the	5
in their first	5
standard care group	5
will be obtained	5
the generalizability of	5
after the first	5
depend on the	5
in the pooled	5
ii trials are	5
continue to be	5
assessed days after	5
in healthcare workers	5
and analysis of	5
the frequency of	5
patients with cancer	5
retrieve the ball	5
profile of the	5
conflicts of interest	5
appear to be	5
is the total	5
the standard care	5
will be informed	5
criteria for adverse	5
contexts of use	5
that aim to	5
should be kept	5
health care systems	5
informed consent form	5
trials and observational	5
distrust in the	5
of the severe	5
placed on the	5
with regards to	5
as in phase	5
the reasons for	5
as a treatment	5
statistical monitoring of	5
than one trial	5
as a potential	5
or not the	5
treatment of the	5
be of interest	5
treatment policy strategy	5
and it is	5
trials in a	5
the help of	5
live oral cholera	5
of hydroxychloroquine for	5
that we did	5
eligible for inclusion	5
of the device	5
and chloroquine in	5
this study are	5
associated with more	5
we identified trials	5
efficient action sequence	5
reduced the risk	5
management of the	5
the united kingdom	5
such as sars	5
natural history of	5
by using the	5
sent to the	5
study of hydroxychloroquine	5
participating in the	5
be applied to	5
results suggest that	5
in this way	5
or mg kg	5
to acknowledge the	5
and adverse events	5
the point of	5
but should be	5
not receive of	5
the study protocol	5
the declaration of	5
in icu patients	5
fda guidance on	5
the remainder of	5
in the present	5
patients and reporting	5
who wish to	5
outside of the	5
reported in the	5
reduction in the	5
will be a	5
directly from the	5
at a dose	5
healthcare workers are	5
are among the	5
is a need	5
to deal with	5
label use of	5
patients in clinical	5
median survival of	5
when patients do	5
data for patients	5
evidence of efficacy	5
our understanding of	5
a tentative solution	5
on trade and	5
of infectious diseases	5
to the medical	5
awake prone positioning	5
respect to the	5
the individual level	5
that we could	5
the pace of	5
and neck cancer	5
stage of the	5
conservation of pangolins	5
of patients to	5
get the ball	5
there will be	5
or nonserious adverse	5
for all three	5
medicines and healthcare	5
may result in	5
of a clinical	5
the gender gap	5
a high incidence	5
to the clinical	5
to the ipad	5
analyses may be	5
to estimate the	5
changing task demands	5
more trials are	5
an overview of	5
be considered for	5
and southeast asia	5
the false discovery	5
of the results	5
all of which	5
patients are not	5
electronic health records	5
of confirmed cases	5
or pneumonic plague	5
of at least	5
trial in phase	5
to south and	5
if the patient	5
clinical trials with	5
results on the	5
reporting data for	5
risk of serious	5
be tested in	5
reported that they	5
a phase i	5
rate in the	5
be recorded in	5
case series and	5
a public health	5
the consent form	5
did not report	5
will be calculated	5
to the drug	5
patients infected with	5
the study period	5
the european union	5
paying research participants	5
the research process	5
and reporting data	5
competing risks analyses	5
grounded theory method	5
responses in the	5
malaria chemoprevention in	5
conditions for each	5
in the number	5
what is the	5
of a harmful	5
majority of the	5
systolic blood pressure	5
of a respirator	5
will be in	5
cell lung cancer	5
the conclusion of	5
the ministry of	5
in a number	5
in other words	5
does not exist	5
to note that	5
stay at home	5
statistical methods and	5
as opposed to	5
median number of	5
health care system	5
in the sense	5
used to treat	5
did not include	5
the testing apparatus	5
for the design	5
in breast cancer	5
small number of	5
streptomycin plus ciprofloxacin	5
malarial drugs for	5
responses in phase	5
is unable to	5
the main limitation	5
to severe psoriasis	5
in the setting	5
of the workshop	5
a change in	5
to consent to	5
be taken to	5
and stored in	5
of their trials	5
of the reviewed	5
a risk of	5
trying out different	5
with a third	5
days alive and	5
ahuja and thatcher	5
for acute respiratory	5
and control groups	5
of systematic errors	5
the inclusion criteria	5
medical research during	5
randomised evaluation of	5
with regulatory agencies	5
and error and	5
practice in the	5
the median number	5
data in clinical	5
in one trial	5
and can be	5
evaluation of covid	5
and the caregiver	5
the state of	5
of the survey	5
of interest for	5
defined based on	5
to achieve this	5
need for mechanical	5
for the management	5
and risk factors	5
after enrollment when	5
composition of the	5
integrity of the	5
was assessed days	5
the time from	5
have also been	5
through trial and	5
and the trial	5
for handling of	5
and mechanical ventilation	5
will be required	5
to address this	5
risk of mortality	5
advantage of the	5
well as a	5
effectiveness and safety	5
is caused by	5
utilization in dementia	5
to changing task	5
acute exacerbations of	5
interpreted with caution	5
in phase was	5
were the most	5
location of the	5
looking at the	5
clinical trial during	5
similar to those	5
the possibility that	5
of serious adverse	5
adverse events will	5
to the sponsor	5
has also been	5
may be helpful	5
to the original	5
resolution of fever	5
and changes in	5
chloroquine in hospitalised	5
effect of standard	5
has never been	5
single target trial	5
transmission in households	5
of good clinical	5
this trial will	5
be possible to	5
a retrospective cohort	5
use of an	5
those of the	5
randomizing patients and	5
trials within cohorts	5
will be included	5
days of remdesivir	5
the gold standard	5
for bubonic plague	5
should be informed	5
other types of	5
for a single	5
a trial and	5
beneficial for covid	5
treatment and care	5
in nursing homes	5
that lead to	5
data can be	5
of all trials	5
medical management arm	5
to the covid	5
of respiratory viruses	5
first presented with	5
the final manuscript	5
randomizing participants compared	5
ministry of health	5
for use in	5
will be offered	5
we used a	5
to be enrolled	5
of clinical studies	5
the pandemic may	5
is to provide	5
to compare the	5
in combination with	5
no conflict of	5
not considered serious	5
to the control	5
events in the	5
and other respiratory	5
across all trials	5
effect of a	5
observational study of	5
as described in	5
conflict of interest	5
of data and	5
healthcare products regulatory	5
the principles of	5
there were no	5
the interpretability of	5
as per the	5
against the target	5
terminology criteria for	5
treatments for coronavirus	5
report on the	5
and the health	5
and implementation of	5
to study treatment	5
azithromycin and chloroquine	5
allowed us to	5
in which children	5
university of medical	5
the research community	5
clinical trials as	5
may be used	5
the change of	5
in case of	5
was applied to	5
aspects of the	5
waiver of consent	5
events with a	5
the first time	5
statistical principles for	5
living systematic reviews	5
full protocol is	5
the treatment policy	5
for a randomized	5
in all the	5
on top of	5
negative correlation between	5
with the general	5
the expense of	5
be beneficial for	5
while on the	5
the era of	5
the size of	5
the pandemic is	5
the first stage	5
mg orally twice	5
the occurrence of	5
trial in the	5
will be given	5
the findings of	5
of pangolins native	5
causal understanding of	5
resource utilization in	5
rest of the	5
benefits and harms	5
in proceedings of	5
of the process	5
the distribution of	5
trial is funded	5
of the available	5
publication of the	5
research involving human	5
personal use scenarios	5
once they are	5
with the ipad	5
recommendations for the	5
preventive treatment with	5
states food and	5
of standard care	5
mashhad university of	5
a need to	5
difference between lopinavir	5
from clinical trials	5
month intervention period	5
informed consent is	5
because they are	5
change of the	5
you get the	5
of the apparatus	5
from phase i	5
side of the	5
the workshop on	5
proceedings of the	5
in the interest	5
are asked to	5
the ability of	5
and clinical trial	5
and approved the	5
the pooled analysis	5
is used to	5
controlled trial date	5
its effects on	5
issues related to	5
trials based on	5
compared to placebo	5
payment for research	5
the week of	5
are described in	5
bubonic or pneumonic	5
are unlikely to	5
we refer to	5
for up to	5
to continue to	5
patient willingness to	5
to test the	5
of treatment and	5
to intensive care	5
which may have	5
to work with	5
clinical trials were	5
of integrative cancer	5
size and the	5
of children in	5
treatment of chronic	5
influenza transmission in	5
k th stage	5
of the two	5
trials were included	5
a sample size	5
that the ipad	5
quintet recruitment intervention	5
will be carried	5
with the trial	5
the intervention group	5
in the pharmaceutical	5
oral cholera vaccine	5
and access to	5
or reject that	5
systematic reviews of	5
in the dexamethasone	5
review of covid	4
compared with standard	4
most commonly used	4
results for the	4
resulted in a	4
statistical analysis plans	4
of critical care	4
event rate in	4
be due to	4
mask use by	4
conducted according to	4
this suggests that	4
of bias trials	4
attending physician who	4
which will be	4
chloroquine with or	4
be affected by	4
of respiratory protection	4
the concept of	4
to patients with	4
to identify and	4
the straw directly	4
for researchers to	4
that the user	4
lopinavir ritonavir plus	4
control and prevention	4
a feasibility study	4
associated with increased	4
forms will be	4
will receive the	4
large proportion of	4
on the time	4
the debate on	4
that in the	4
management of copd	4
measures such as	4
of the overall	4
a good enough	4
interventions to interrupt	4
trial design is	4
treated with a	4
voluntary use of	4
study treatment discontinuation	4
pwd and the	4
the hpa axis	4
behaviour and cognition	4
at the conclusion	4
olds made efficient	4
with mild to	4
pnif and npr	4
the key elements	4
compliance with the	4
and routinely collected	4
be considered when	4
a majority of	4
in the trials	4
science and technology	4
study designs and	4
and hand hygiene	4
and recommendations for	4
public health practice	4
and on day	4
data sharing and	4
geriatric clinical trials	4
using the following	4
systematic review with	4
for the success	4
cancer patients in	4
results can be	4
and prevention of	4
wei bushen yiqi	4
also been used	4
than the younger	4
accessible from the	4
clinical trials related	4
randomly assigned to	4
window of opportunity	4
of the key	4
azithromycin as a	4
the first case	4
purpose of this	4
their time and	4
the tablet with	4
malarial drug safety	4
two or more	4
mg kg every	4
removing the straw	4
straw directly below	4
expediting dissemination of	4
of randomized trials	4
by healthcare workers	4
offers of payment	4
most efficient solution	4
in the who	4
that were not	4
by the norwegian	4
receive placebo plus	4
discharge from the	4
or without a	4
as adjunctive therapy	4
department of health	4
the patients will	4
the anatomy of	4
of the first	4
be considered to	4
or a fourfold	4
relative to the	4
the use and	4
ageing and health	4
in antibody titre	4
of included trials	4
efficiency in phase	4
the significance of	4
quadrivalent rhesus rotavirus	4
streptomycin and ciprofloxacin	4
and after the	4
the medical community	4
generalizability of the	4
cannabis use disorder	4
switch to oral	4
were unable to	4
different categories of	4
disruptions due to	4
the largest trial	4
improve health and	4
authors contributed to	4
be administered by	4
of this vaccine	4
due to contact	4
should be used	4
realistic intervention effects	4
for research in	4
of this trial	4
we have not	4
the sponsor and	4
the probability of	4
of baseline severity	4
genv proposes to	4
infection in a	4
coronavirus disease in	4
was used for	4
consultation with a	4
reduce the need	4
estimates of vaccine	4
the criteria for	4
different action sequences	4
with a specific	4
as outlined in	4
there have been	4
low to very	4
is to define	4
will be considered	4
be required for	4
studies may be	4
over time and	4
a timely fashion	4
conduction of clinical	4
length of stay	4
randomized control trial	4
a small number	4
trial efficacy and	4
our aim was	4
introduction of new	4
of dexamethasone on	4
reporting of clinical	4
assess the effect	4
should be evaluated	4
interventions for covid	4
mind at home	4
when first presented	4
medical research involving	4
and timing of	4
relies on the	4
tests will be	4
effects of all	4
body of evidence	4
evaluate the clinical	4
in the elderly	4
trials and their	4
number of registered	4
occur due to	4
drugs in pregnancy	4
authors declare no	4
this is especially	4
to limit the	4
sequence will be	4
action sequences used	4
high flow therapy	4
the treatment group	4
the interim analysis	4
based upon the	4
the trials that	4
relevant to the	4
a coefficient of	4
work from home	4
the current situation	4
to carry out	4
cause mortality with	4
effects of remdesivir	4
in the statistical	4
the quality and	4
contrast to phase	4
coronavirus named severe	4
not have a	4
to contact with	4
leading to a	4
across age groups	4
international classification of	4
eligible patients will	4
the writing group	4
terms of timing	4
is imperative that	4
to the treatment	4
which is the	4
specified in the	4
the final cumulative	4
deemed clinically appropriate	4
remainder of the	4
of the network	4
with the it	4
study and the	4
the study of	4
attention to the	4
be viewed as	4
of treatment effects	4
we consider that	4
description of the	4
septoplasty versus medical	4
would have agreed	4
in task configuration	4
trials and the	4
find the food	4
interpretation of data	4
will be published	4
funded by the	4
for the scientific	4
patient information sheet	4
of the lack	4
a need for	4
supplementary video s	4
the inclusion and	4
should be the	4
in need of	4
determined by the	4
a focus on	4
research may be	4
the eligibility criteria	4
of the sponsor	4
of the questionnaire	4
effect of covid	4
the quintet recruitment	4
the study drug	4
and azithromycin as	4
to be recruited	4
is supported by	4
the conditions for	4
along with the	4
of access to	4
recorded in the	4
of care for	4
able to swallow	4
of its use	4
the nose and	4
all the data	4
frequency oscillatory ventilation	4
charge of the	4
use of rescue	4
for data management	4
creative commons attribution	4
the medical research	4
evaluate the impact	4
clinical development of	4
to consider the	4
our empirical material	4
patients in each	4
other forms of	4
novel coronavirus disease	4
need for a	4
might need to	4
familiar formatting has	4
outcomes in the	4
to complete their	4
safety monitoring boards	4
such as covid	4
order to overcome	4
and secondary outcomes	4
can be applied	4
see supplementary video	4
to do something	4
for six trials	4
phase iii rcts	4
and there are	4
in some cases	4
were reported in	4
framework for the	4
a pathway for	4
transferred to the	4
about how to	4
trial is a	4
in detail in	4
involved in clinical	4